Apolipoprotein-E (APOE) genotyping predicts Alzheimer's Disease (AD) with 100% accuracy in US study
This article was originally published in Clinica
US researchers at Duke University Medical Center, North Carolina, found that apolipoprotein-E genotyping had a 100% positive predictive value in 57 demented patients confirmed by post mortem as having Alzheimer's disease. Reporting their results in the Lancet (July 13th), Prof A Roses and colleagues say that both the specificity and positive predictive value associated with the e4 allele were 100% for AD. None of the 10 demented non-AD patients carried the allele, while all the patients with APOE-e4 had AD. The negative predictive value was 42%.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.